Selective analysis of Nadifloxacin in human plasma samples using a molecularly imprinted polymer-based solid-phase extraction proceeded by UPLC-DAD analysis

Document Type

Article

Publication Date

2020

Abstract

Nadifloxacin is a second-generation fluoroquinolone antibacterial agent developed for the treatment of some dermatological infections. In this work, a molecularly imprinted polymer was synthesized and characterized. The best binding performance was found for the polymer prepared by the non-covalent approach using the ratio of 1:4:20 (Nadifloxacin: methacrylic acid: ethylene glycol dimethacrylate). This molecularly imprinted polymer was used as a sorbent in solid-phase extraction for the selective purification of Nadifloxacin to monitor its traces concentration in human plasma samples to evaluate its systemic absorption after topical application. Then, a quantitative determination using ultra-performance liquid chromatography was performed. The prepared polymer shows selective recognition of Nadifloxacin where the recovery reached 96.00% and 92.00% for Nadifloxacin in the presence of structural related and unrelated analogs, respectively. The UPLC method was validated according to bioanalytical method validation guidelines where the method is linear in range from 0.1 to 100 µg mL−1 with correlation coefficient 0.9998, the lower limit of quantification was 100 ng mL−1. The accuracy, intra-day and inter-day precision of the method ranged from 99.20% to 114.00%, 2.44% to 4.72% and 2.44% to 4.34%, respectively. The method was then applied successfully for the selective extraction of Nadifloxacin traces in real human plasma samples without prior purification.

Link to Full Text

Share

COinS